Loading stock data…
CeriBell (CBLL)
$19.96-0.02 (-0.10%)
After Hours$19.96+0.00 (+0.00%)· Last close Jun 29
CeriBell, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
CeriBell, Inc. in the Healthcare sector is trading at $19.96 with a market capitalization of $702M. Wall Street consensus targets $26.86 (7 analysts), implying a +34.6% move over the next 12 months. The stock is currently 18% below its 52-week high of $24.33, remaining 12.7% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +34.6% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $26.49M↑ | $24.78M↑ | $22.59M↑ | $21.20M↑ | $20.49M |
| Gross Profit | $23.12M↑ | $21.64M↑ | $19.94M↑ | $18.68M↑ | $18.01M |
| Operating Income | -$20.75M↓ | -$14.60M↑ | -$14.65M↑ | -$14.95M↓ | -$14.21M |
| Net Income | -$19.74M↓ | -$13.53M↓ | -$13.46M↑ | -$13.64M↓ | -$12.78M |
Peer Comparison
JNJUNHPFE
Fundamentals
CeriBell, Inc. operates as a medical technology company in the United States. It develops the Ceribell System, a novel and point-of-care EEG platform specifically designed to address the unmet needs of patients in the acute care setting. The company ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$702.32M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-42.87%
Volume
Today's trading volume
229,143
Recent News
Is CeriBell, Inc. (CBLL) Among the Best Brain-Computer Interface Stocks to Buy?
CeriBell, Inc. (NASDAQ:CBLL) is among the Best Brain-Computer Interface Stocks. On June 8, CeriBell, Inc. (NASDAQ:CBLL) reported a study published in Critical Care Medicine that higher AI-detected seizure burden is linked with increased odds of disability results at discharge. It analyzed 359 adult patients across three academic centers. The company said patients with a peak seizure […]
CeriBell Sees ‘Early Innings’ Growth as Hospital Accounts and Usage Hit Records
CeriBell (NASDAQ:CBLL) executives said the company’s first-quarter results reflected continued momentum in both new account additions and increased usage among existing hospital customers, while outlining early progress in new clinical areas including neonatal seizure monitoring and delirium. Speak
CeriBell Inc (CBLL) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Market ...
CeriBell Inc (CBLL) reports impressive revenue growth and market expansion, despite facing increased operating expenses and litigation costs.
CeriBell Q1 Earnings Call Highlights
CeriBell (NASDAQ:CBLL) reported first-quarter revenue growth of 29% and raised its full-year outlook, as management cited higher usage of its seizure monitoring system and the company’s strongest quarter of net new hospital additions since becoming public. On the company’s earnings call, Co-founder
CeriBell (CBLL) Q1 2026 Earnings Transcript
Earlier today, CeriBell, Inc. issued a press release announcing financial results for the quarter ended 03/31/2026. Beyond continued progress in penetrating our core seizure market, we delivered two major milestones that mark inflection points in the evolution of our platform.